Cadrenal Therapeutics to Initiate Phase 2a Trial for CAD-1005
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 15 2026
0mins
Cadrenal Therapeutics announced that it plans to initiate a Phase 2a proof-of-concept clinical trial of its lead drug candidate, CAD-1005, being studied to prevent Acute Kidney Injury in high-risk patients undergoing cardiac surgery. The trial is expected to begin later this year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVKD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVKD
About CVKD
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cadrenal Therapeutics Secures $3 Million Financing Agreement
- Financing Agreement Details: Cadrenal Therapeutics has entered into an agreement with a single healthcare investor to issue 960,000 shares of common stock along with C-1 and C-2 series warrants, expecting total gross proceeds of $3 million, with an additional potential of $5.8 million if warrants are fully exercised, thereby enhancing the company's liquidity for future R&D.
- Planned Use of Funds: The net proceeds from this financing will be directed towards working capital, anticipated to extend the cash runway into the first quarter of 2027, and potentially into the second half of 2027 if warrants are fully exercised, facilitating partnership opportunities in Kawasaki Disease and CSA-AKI.
- Warrant Terms: The C-1 series warrants have an exercise price of $3.00 per share and will be exercisable upon stockholder approval, while the C-2 series warrants will be immediately exercisable upon issuance, providing the company with flexible capital-raising options and bolstering market confidence.
- Market Reaction Expectations: The offering is expected to close on July 1, 2026, and despite potential market volatility, this move strengthens the company's competitive position in the treatment of immune and thrombotic conditions, likely attracting more investor interest.
See More
Cadrenal Therapeutics Prices $3 Million Private Placement
- Funding Amount: Cadrenal Therapeutics (CVKD) has successfully priced a private placement expected to generate approximately $3 million, which will provide essential funding for the company's research and operations.
- Use of Proceeds: The funds raised will primarily be allocated to advancing Cadrenal's clinical trials and product development, aiming to accelerate its competitiveness in the biopharmaceutical sector.
- Market Reaction: The market has responded positively to Cadrenal's private placement, with investors expressing optimism about the company's future growth potential, which may have a favorable impact on its stock price.
- Strategic Implications: This financing enhances Cadrenal's financial flexibility, enabling it to better navigate industry challenges and seize market opportunities, thereby driving long-term growth.
See More
Cadrenal Therapeutics Secures $8.8 Million Financing Deal
- Financing Agreement: Cadrenal Therapeutics has entered into a definitive agreement with a single healthcare-focused institutional investor for a private placement of up to $8.8 million, including $3 million upfront from the sale of 960,000 shares and related C-1 and C-2 warrants, priced at $3.125 per share, indicating strong market confidence in its financing capabilities.
- Warrant Potential: If fully exercised, the warrants could generate an additional $5.8 million in gross proceeds, which would not only enhance the company's financial flexibility but also potentially fund future R&D and market expansion efforts.
- Clear Use of Funds: The net proceeds from this financing are expected to extend the company's cash runway into Q1 2027, and possibly into the second half of 2027, reflecting strategic decisions in developing Tecarfarin and CAD-1005 to address specific medical needs.
- Stable Market Performance: CVKD's stock has traded between $2.55 and $14.64 over the past year, closing at $3.34, up 10.60% from the previous trading day, demonstrating investor confidence in the company's future prospects.
See More
Cadrenal Seeks Rare Pediatric Disease Designation for Tecarfarin
- Drug Application Progress: Cadrenal Therapeutics is preparing to file for Rare Pediatric Disease Designation for Tecarfarin, aimed at assisting children with Kawasaki disease facing lifelong risks from blood clot complications, demonstrating the company's strategic focus on unmet medical needs.
- Market Potential: Kawasaki disease is the leading cause of acquired heart disease in children in developed nations, with up to 25% of untreated patients developing coronary artery aneurysms, and the development of Tecarfarin is expected to improve anticoagulation therapy outcomes for these children, thereby reducing the risks of heart attacks and sudden cardiac death.
- Regulatory Advantage: If the FDA grants RPDD for Tecarfarin, Cadrenal would be eligible for a Priority Review Voucher (PRV), which has recently sold for between $180 million and $205 million on the market, highlighting its potential economic value.
- Dual-Track Strategy: Cadrenal is employing a dual-track portfolio strategy, advancing not only Tecarfarin but also the CAD-1005 program, a first-in-class 12-LOX inhibitor targeting Heparin-Induced Thrombocytopenia, showcasing the company's broad positioning in critical care areas.
See More
Cadrenal to Showcase New Drug Pipeline at BIO Convention
- Rare Disease Initiative: Cadrenal plans to submit a Rare Pediatric Disease Designation request to the FDA for tecarfarin, targeting Kawasaki disease in children, which could lead to a Priority Review Voucher valued at up to $200 million, significantly enhancing the company's market position in pediatric heart disease treatment.
- Clinical Trial Readiness: As a next-generation Vitamin K antagonist, tecarfarin aims to overcome the metabolic limitations of warfarin, providing more stable anticoagulation, which is expected to improve treatment outcomes for children with Kawasaki disease and reduce risks of thrombosis and bleeding, addressing a critical unmet medical need.
- Dual-Track Strategy Showcase: At the 2026 BIO International Convention, Cadrenal will present its dual-track portfolio strategy, highlighting the clinical progress of CAD-1005 as a first-in-class 12-LOX inhibitor, targeting the thrombotic disease market, which is anticipated to attract partnerships from global pharmaceutical companies.
- Market Opportunity: With Kawasaki disease incidence rates in Japan and East Asia being 10 to 15 times higher than in Western nations, Cadrenal's regional rare disease track will leverage this market opportunity to enhance the clinical trial design for tecarfarin, increasing collaboration potential with local pharmaceutical firms.
See More
Cadrenal Therapeutics Plans Phase 2a Trial for CAD-1005 to Address Acute Kidney Injury
- New Indication Expansion: CAD-1005's addition of the Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) indication targets a market affecting 35,000 U.S. patients annually, representing a $1 billion opportunity and addressing a significant gap in FDA-approved therapies, thereby creating substantial commercial prospects for Cadrenal Therapeutics.
- Clinical Trial Plans: The planned Phase 2a trial, set to begin in 2026, aims to evaluate the safety and efficacy of CAD-1005 in high-risk cardiac surgery patients, which is expected to provide critical data supporting the company's strategic partnerships in both acute kidney injury and thrombotic conditions.
- Capital Efficiency Enhancement: This trial leverages existing hospital ICU infrastructure and an intravenous formulation to offer an efficient critical care solution, aimed at attracting global pharmaceutical partners and further enhancing Cadrenal's market position.
- Strategic Collaboration Opportunities: Cadrenal plans to discuss the CSA-AKI clinical strategy and its implications for CAD-1005's broader development at the 2026 BIO International Convention, which is anticipated to create favorable conditions for securing non-dilutive collaborations to support pipeline expansion.
See More
Cadrenal Therapeutics Secures $3 Million Financing Agreement
- Financing Agreement Details: Cadrenal Therapeutics has entered into an agreement with a single healthcare investor to issue 960,000 shares of common stock along with C-1 and C-2 series warrants, expecting total gross proceeds of $3 million, with an additional potential of $5.8 million if warrants are fully exercised, thereby enhancing the company's liquidity for future R&D.
- Planned Use of Funds: The net proceeds from this financing will be directed towards working capital, anticipated to extend the cash runway into the first quarter of 2027, and potentially into the second half of 2027 if warrants are fully exercised, facilitating partnership opportunities in Kawasaki Disease and CSA-AKI.
- Warrant Terms: The C-1 series warrants have an exercise price of $3.00 per share and will be exercisable upon stockholder approval, while the C-2 series warrants will be immediately exercisable upon issuance, providing the company with flexible capital-raising options and bolstering market confidence.
- Market Reaction Expectations: The offering is expected to close on July 1, 2026, and despite potential market volatility, this move strengthens the company's competitive position in the treatment of immune and thrombotic conditions, likely attracting more investor interest.
See More
Cadrenal Therapeutics Prices $3 Million Private Placement
- Funding Amount: Cadrenal Therapeutics (CVKD) has successfully priced a private placement expected to generate approximately $3 million, which will provide essential funding for the company's research and operations.
- Use of Proceeds: The funds raised will primarily be allocated to advancing Cadrenal's clinical trials and product development, aiming to accelerate its competitiveness in the biopharmaceutical sector.
- Market Reaction: The market has responded positively to Cadrenal's private placement, with investors expressing optimism about the company's future growth potential, which may have a favorable impact on its stock price.
- Strategic Implications: This financing enhances Cadrenal's financial flexibility, enabling it to better navigate industry challenges and seize market opportunities, thereby driving long-term growth.
See More
Cadrenal Therapeutics Secures $8.8 Million Financing Deal
- Financing Agreement: Cadrenal Therapeutics has entered into a definitive agreement with a single healthcare-focused institutional investor for a private placement of up to $8.8 million, including $3 million upfront from the sale of 960,000 shares and related C-1 and C-2 warrants, priced at $3.125 per share, indicating strong market confidence in its financing capabilities.
- Warrant Potential: If fully exercised, the warrants could generate an additional $5.8 million in gross proceeds, which would not only enhance the company's financial flexibility but also potentially fund future R&D and market expansion efforts.
- Clear Use of Funds: The net proceeds from this financing are expected to extend the company's cash runway into Q1 2027, and possibly into the second half of 2027, reflecting strategic decisions in developing Tecarfarin and CAD-1005 to address specific medical needs.
- Stable Market Performance: CVKD's stock has traded between $2.55 and $14.64 over the past year, closing at $3.34, up 10.60% from the previous trading day, demonstrating investor confidence in the company's future prospects.
See More
Cadrenal Seeks Rare Pediatric Disease Designation for Tecarfarin
- Drug Application Progress: Cadrenal Therapeutics is preparing to file for Rare Pediatric Disease Designation for Tecarfarin, aimed at assisting children with Kawasaki disease facing lifelong risks from blood clot complications, demonstrating the company's strategic focus on unmet medical needs.
- Market Potential: Kawasaki disease is the leading cause of acquired heart disease in children in developed nations, with up to 25% of untreated patients developing coronary artery aneurysms, and the development of Tecarfarin is expected to improve anticoagulation therapy outcomes for these children, thereby reducing the risks of heart attacks and sudden cardiac death.
- Regulatory Advantage: If the FDA grants RPDD for Tecarfarin, Cadrenal would be eligible for a Priority Review Voucher (PRV), which has recently sold for between $180 million and $205 million on the market, highlighting its potential economic value.
- Dual-Track Strategy: Cadrenal is employing a dual-track portfolio strategy, advancing not only Tecarfarin but also the CAD-1005 program, a first-in-class 12-LOX inhibitor targeting Heparin-Induced Thrombocytopenia, showcasing the company's broad positioning in critical care areas.
See More
Cadrenal to Showcase New Drug Pipeline at BIO Convention
- Rare Disease Initiative: Cadrenal plans to submit a Rare Pediatric Disease Designation request to the FDA for tecarfarin, targeting Kawasaki disease in children, which could lead to a Priority Review Voucher valued at up to $200 million, significantly enhancing the company's market position in pediatric heart disease treatment.
- Clinical Trial Readiness: As a next-generation Vitamin K antagonist, tecarfarin aims to overcome the metabolic limitations of warfarin, providing more stable anticoagulation, which is expected to improve treatment outcomes for children with Kawasaki disease and reduce risks of thrombosis and bleeding, addressing a critical unmet medical need.
- Dual-Track Strategy Showcase: At the 2026 BIO International Convention, Cadrenal will present its dual-track portfolio strategy, highlighting the clinical progress of CAD-1005 as a first-in-class 12-LOX inhibitor, targeting the thrombotic disease market, which is anticipated to attract partnerships from global pharmaceutical companies.
- Market Opportunity: With Kawasaki disease incidence rates in Japan and East Asia being 10 to 15 times higher than in Western nations, Cadrenal's regional rare disease track will leverage this market opportunity to enhance the clinical trial design for tecarfarin, increasing collaboration potential with local pharmaceutical firms.
See More
Cadrenal Therapeutics Plans Phase 2a Trial for CAD-1005 to Address Acute Kidney Injury
- New Indication Expansion: CAD-1005's addition of the Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) indication targets a market affecting 35,000 U.S. patients annually, representing a $1 billion opportunity and addressing a significant gap in FDA-approved therapies, thereby creating substantial commercial prospects for Cadrenal Therapeutics.
- Clinical Trial Plans: The planned Phase 2a trial, set to begin in 2026, aims to evaluate the safety and efficacy of CAD-1005 in high-risk cardiac surgery patients, which is expected to provide critical data supporting the company's strategic partnerships in both acute kidney injury and thrombotic conditions.
- Capital Efficiency Enhancement: This trial leverages existing hospital ICU infrastructure and an intravenous formulation to offer an efficient critical care solution, aimed at attracting global pharmaceutical partners and further enhancing Cadrenal's market position.
- Strategic Collaboration Opportunities: Cadrenal plans to discuss the CSA-AKI clinical strategy and its implications for CAD-1005's broader development at the 2026 BIO International Convention, which is anticipated to create favorable conditions for securing non-dilutive collaborations to support pipeline expansion.
See More
